Me. Int Clin Psychopharmacol 1996, 11(2):559.Conclusions In conclusion, the outcomes of the PETiT and SF-12 assessments indicate that patients with schizophrenia who switch to lurasidone from other ERβ Modulator Storage & Stability antipsychotics might expertise improvements in HRQoL within six weeks of remedy. Further investigation from the effects of longerterm lurasidone therapy on top quality of life outcomes and patient-reported perception of switching to lurasidone is warranted.Awad et al. BMC Psychiatry 2014, 14:53 http://biomedcentral/1471-244X/14/Page ten of13. Lieberman JA, Stroup TS, McEvoy JP, Swartz MS, Rosenheck RA, Perkins DO, Keefe RS, Davis SM, David CE, Lebowitz BD, Serious J, Hsiao JK: Effectiveness of antipsychotic drugs in patients with chronic schizophrenia. N Engl J Med 2005, 353:1209223. 14. Nyhuis AW, Faries DE, Ascher-Svanum HA, Stauffer VL, Kinon BJ: Predictors of switching antipsychotic medications inside the treatment of schizophrenia. BMC Psychiatry 2010, 10:75. 15. Puschner B, Angermeyer MC, Leese M, Thornicroft G, Schene A, Kikkert M, Burti L, CYP2 Inhibitor site Tansella M, Becker T: Course of adherence to medication and top quality of life in people with schizophrenia. Psychiatry Res 2009, 165:2243. 16. Falkai P: Limitations of existing therapies: why do sufferers switch therapies Eur Neuropsychopharmacol 2008, three:S135. 17. Lacro JP, Dunn LB, Dolder CR, Leckband SG, Jeste DV: Prevalence of and threat things for medication nonadherence inpatients with schizophrenia: a extensive assessment of current literature. J Clin Psychiatry 2002, 63:89209. 18. Freudenreich O, Cather C, Evins AE, Henderson DC, Goff DC: Attitudes of schizophrenia outpatients toward psychiatric medications: partnership to clinical variables and insight. J Clin Psychiatry 2004, 65(ten):1372. 19. Santone G, Rucci P, Muratori ML, Monaci A, Ciarafoni C, Borsetti G: Attitudes toward medication in inpatients with schizophrenia: a cluster analytic strategy. Psychiatry Res 2008, 158(three):3244. 20. Schennach-Wolff R, Jager M, Seemuller F, Obermeier M, Messer T, Laux G, Pfeiffer H, Naber D, Schmidt LG, Gaebel W, Klosterkotter J, Heuser I, Maier W, Lemke MR, Ruther E, Klingberg S, Gastpar M, Moller HJ, Riedel M: Attitude towards adherence in sufferers with schizophrenia at discharge. J Psychiatr Res 2009, 43(16):129401. 21. Adelufosi AO, Adebowale TO, Abayomi O, Mosanya JT: Medication adherence and excellent of life among Nigerian outpatients with schizophrenia. Gen Hosp Psychiatry 2012, 34:72. 22. Awad AG, Voruganti LN: New antipsychotics, compliance, good quality of life, and subjective tolerability are individuals better off Can J Psychiatry 2004, 49:297. 23. Morken G, Widen JH, Grawe RW: Non-adherence to antipsychotic medication, relapse and rehospitalisation in recent-onset schizophrenia. BMC Psychiatry 2008, eight:32. 24. Citrome L: Iloperidone, asenapine, and lurasidone: a short overview of 3 new second-generation antipsychotics. Postgraduate Medicine 2011, 123:15362. 25. McEvoy JP, Citrome L, Hernandez D, Cucchiaro J, Hsu J, Pikalov A, Loebel A: Effectiveness of lurasidone in schizophrenia or schizoaffective disorder sufferers switched from other antipsychotics: a randomized, six-week, open-label study. J Clin Psychiatry 2013, 74(two):170. 26. Buckley PF: Receptor-binding profiles of antipsychotics: clinical strategies when switching in between agents. J Clin Psychiatry 2007, 68(six):five. 27. Citrome L, Nasrallah HA: On-label around the table: what the package insert informs us concerning the tolerability profile of oral atypical antipsychotics,.